On May 20, 2026, Claritas Axis – an FDA compliance and Drug Supply Chain Security Act (DSCSA) readiness platform that conducts focused, practice-level assessments specifically for physician-owned medical practices – announced a new 10-question free Drug Supply Chain Readiness Snapshot to help medical spas, aesthetic practices, and wellness clinics assess whether their drug documentation is inspection-ready.
The initiative comes at a time where a growing number of aesthetic practices may be underestimating their exposure to federal drug supply requirements, as the Drug Supply Chain Security Act (DSCSA), requires any aesthetic practice that purchases and administers prescription drugs in-office can fall under the law's dispenser requirements.
Related: Demand Skyrockets for IV Hydration Therapy Business Academy
Medical spas and aesthetic practices commonly use neuromodulators like Botox, Dysport, and Xeomin. Dermal filler programs rely on prescription products including hyaluronic acid and biostimulatory injectables. Many practices have expanded into peptide therapies, IV wellness protocols, and compounded formulations sourced from specialty pharmacies. Weight management programs increasingly incorporate GLP-1 medications and related pharmaceuticalprotocols. In other words, DSCSA reaches much further into aesthetic medicine than many practices may assume—and the regulatory environment is tightening.
James Strafuss, founder of Claritas Axis, frames the issue as a significant awareness gap, shaped in part by confusion over how directly these standards apply to aesthetic practices. Many MedSpas and Aesthetics clinics did not fully understand that DSCSA reached them, even though full enforcement began in 2023. With federal and state enforcement now working in tandem, practices may be more exposed than they realize.
Focusing first on inspection readiness, Claritas Axis notes many aesthetic practices have never looked at their everyday drug workflows through an inspector's eyes. Buying from a trusted source and saving invoices may feel sufficient, but DSCSA expects more structured documentation and written procedures than many offices currently maintain.
Claritas Axis’s 10-question free Drug Supply Chain Readiness Snapshot gives medical spas, aesthetic practices, and wellness clinics a practical way to gauge risk before an inspector does. It can quickly show whether obvious gaps may exist and help MedSpa owners and medical directors determine whether deeper review is needed before documentation questions become a larger problem.
